Veracyte VCYT Other Testing Revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's other testing revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's other testing revenue — total revenue?
- Veracyte (VCYT) reported other testing revenue — total revenue of $4.2M in Q1 2026.
- How has Veracyte's other testing revenue — total revenue changed year-over-year?
- Veracyte's other testing revenue — total revenue increased by 950.0% year-over-year, from $400K to $4.2M.
- What is the long-term trend for Veracyte's other testing revenue — total revenue?
- Over 4 years (2021 to 2025), Veracyte's other testing revenue — total revenue has grown at a 54.1% compound annual growth rate (CAGR), from $1.1M to $6.2M.
- What does other testing revenue — total revenue mean?
- This metric represents the total revenue generated from diagnostic testing services that fall outside of the company's primary or core product lines. It captures income from ancillary testing offerings, pilot programs, or specialized services that contribute to the company's diversified revenue stream. Monitoring this segment helps investors assess the growth potential and market adoption of secondary diagnostic platforms.